5 results about "Antineoplastic drug" patented technology

The application discloses a ternary supramolecular nanoparticle based on a cyclodextrin-opened cucurbituril double host, which is prepared by adding an organic solvent containing a guest hydrophobic pyridine-pyrrole boron derivative and a hydrophobic adamantyl disulfide modified antitumor drug into an aqueous solution of water-soluble cyclodextrin-opened cucurbituril, and then performing ultrasonic treatment, standing, self-assembly through host-guest interaction between molecules, dialysis in the dark, filtration and drying, so as to obtain the ternary supramolecular nanoparticle. The ternary supramolecular nanoparticle has the advantages of mild preparation conditions, simple operation, uniform size and good stability, and can significantly improve the water solubility of the hydrophobic drugs BP and AD-SS-D. The application realizes a significant synergistic effect of photodynamic therapy and chemotherapy, can effectively induce cancer cell apoptosis and inhibit the migration of the cancer cells, and has low toxicity to normal cells, and provides a safe and efficient novel nanoparticle drug delivery platform for multifunctional synergistic antitumor treatment.

The invention discloses a method for stereoselectively synthesizing a chiral triarylmethane thioether compound with antitumor biological activity, and relates to the technical field of medicine synthesis. According to the invention, a seven-membered ring system 3-indolyl [1, 4] sulfur azacycloheptane compound is used as a raw material, an asymmetric Friedel-Crafts alkylation reaction with nucleophilic indole is realized through a new strategy that a spiro chiral phosphonic acid catalyst catalyzes bond breaking of a carbon-nitrogen bond, a high-quality path is provided for synthesis of a chiral triarylmethane thioether compound, and the chiral triarylmethane thioether compound has a wide application prospect. Meanwhile, the reaction has the characteristics of easily available raw materials and mild conditions, and also has the technical advantages of high enantioselectivity and high atom economy. The chiral triarylmethane thioether compound provided by the invention has an obvious inhibition effect on the growth of human cervical cancer cells (HeLa), pancreatic cancer cells (Panc-1) and human bone marrow neuroblastoma cells (Sy5Y), shows good anti-tumor biological activity, and has important positive significance for promoting the research and development of anti-tumor drugs.

The application belongs to the field of biological medicine, and discloses a 2-methyl quinoline derivative with a structure as shown in formula I, R is selected from substituted phenyl as shown in the formula, n is an integer of 1-5, R1 is selected from C1-C3 alkyl, halogen-substituted C1-C3 alkyl, C1-C3 alkoxy, halogen-substituted C1-C3 alkoxy, 3,4-methylenedioxy, phenyl and -NR3R4; R3 and R4 are independently selected from H and C1-C3 alkyl; however, the substituted phenyl does not include p-methoxyphenyl and 3-amino-4-methoxyphenyl; X is selected from C and N, and R2 is selected from H and C1-C3 alkyl, but X cannot be selected from C and R2 cannot be selected from H at the same time. The 2-methyl quinoline derivative has good antitumor activity, and the toxicity to human normal cells is weaker than the toxicity to cancer cells. The application discloses application of the 2-methyl quinoline derivative in preparation of an antitumor drug.

The present disclosure concerns fixed dosing of anti-clusterin antibodies, or an antigen binding fragments thereof for treatment of cancer. Methods of treating cancer with a combination therapy comprising an anti-clusterin antibody or an antigen binding fragment thereof and a chemotherapeutic combination comprising two or more antineoplastic agents are also disclosed herein. The present disclosure also provides treatment of metastatic colorectal cancer with anti-clusterin antibodies or antigen binding fragments thereof as a single agent or in combination with FOLFOX for resection of metastases.

The application discloses an oral anti-tumor drug subject home standard medicine taking reminding and monitoring system, which comprises an event collection module, a state graph generation module, a medicine taking state inference module, a symptom state inference module, an iterative correction module and a reminding action determination module. The system collects multi-source event data of the subject and stores them in a unified event warehouse, generates an executable medicine taking state graph according to a drug administration scheme, infers the medicine taking state of each dose by combining observation characteristics and legal transfer conditions, and forms a medicine taking state timeline. The system also performs time backtracking inference on symptom reporting data by taking the timeline as a constraint, and forms a symptom state timeline. The system iteratively corrects the two types of timelines within a sliding time window, outputs a joint inference result, and determines the reminding action type according to the result, thereby improving the accuracy and standardization of home medicine taking reminding and monitoring.